Lenacapavir is approved under the brand name Sunlenca in the United States for treating HIV-1 infection in heavily treatment-experienced adults with multi-drug-resistant infections. GILD also ...

Drug-resistance amino acids known in HIV-1 [36] are shown in bold. Amino acids that are the same as those of the reference HIV-1 HXB2 are shown as bars. † Consensus amino acid sequences were ...

There are biological and clinical questions facing the field of HIV genotyping such as the need to better define the level of sensitivity required to detect drug-resistant variants, how different ...

We don't understand it well, but it doesn't happen as much as it used to, thanks to antiretroviral therapy (ART), the drugs that treat HIV ... Progressive resistance training can help you develop ...

Learn about HIV stages, prevention methods and treatment options including modern testing approaches for better health management in 2025.

This six-month injectable has been found by two international studies to provide nearly complete protection against HIV infection; an unprecedented result. Lenacapavir, an injectable option for ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the end of January, alarming community activists who worry the move will ...

Merck's DOR/ISL regimen demonstrated non-inferiority to bART and BIC/FTC/TAF in two pivotal Phase 3 trials for adults with HIV-1 ... Merck’s investigational drug, is being evaluated in multiple ...

MSD's new drug combination shows promise in HIV-1 treatment, aiming to offset potential losses from Keytruda's patent ...

“The defendants lied to investors and the public — including during the height of the COVID-19 pandemic — about a drug that purportedly treated HIV and COVID-19 in order to artificially ...

A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as claimed in social media posts. Apart from rare and dangerous stem cell ...